Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines

Oral Oncology

Volumn 35, Issue 5, 1999, Pages 476-483

  Akanuma, D ^a   Uzawa, N ^a   Yoshida, M A ^a   Negishi, A ^a   Amagasa, T ^a   Ikeuchi, T ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Homozygous deletion; Methylation; Oral squamous cell carcinoma; p16; Point mutation

Indexed keywords

ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE MAPPING; HUMAN; HUMAN CELL; MOUTH CANCER; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION; GENES, P16; HUMANS; MOUTH NEOPLASMS; POINT MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0032781820     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(99)00020-2     Document Type: Article

References (29)

1. Kamb A., Gruis N.A, Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day III R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
2. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.A., Sheahan M.D., Clark Jr W.H., Tucker M.A., Dracopoli N.C. Germline p16 mutations in familial melanoma. Nature Genetics. 8:1994;15-26.
3. Jen J., Harper W., Bigner S.H., Bigner D.B., Papadopoulos N., Markowiz S., Willson J.K.V., Kinzler K.W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Research. 54:1994;6353-6358.
4. Liu Q., Neuhausen S., McClure M., Frye C., Weaver-Feldhaus J., Gruis N.A., Eddington K., Allalunis-Turner M.J., Skolnick M.H., Fujimura F.K., Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene. 10:1995;1061-1067.
5. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., Rutter J.L., Buckler A., Gabrielson E., Tockman M., Cho K.R., Hedrick L., Bova G.S., Isaacs W., Koch W., Schwab D., Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics. 11:1995;210-212.
6. Liggett W.H. Jr., Sidransky D Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology. 16:1998;1197-1206.
7. Parkin D.M., Pisani P., Ferlay J Estimates of the worldwide incidence of eighteen major cancer in 1985. International Journal of Cancer. 54:1993;594-606.
8. Nawroz H., Van der Riet P., Hruban R.H., Koch W., Ruppert J.M., Sidransky D Allelotype of head and neck squamous cell carcinoma. Cancer Research. 54:1994;1152-1155.
9. Field J.K., Kiaris H., Risk J.M., Tsiriyotis C., Adamson R., Zoumpourlis V., Rowley H., Taylor K., Whittaker J., Howard P., Beirne J.C., Gosney J.R., Woolgar J., Vaughan E.D., Spandidos D.A., Jones A.S. Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. British Journal of Cancer. 72:1995;1180-1188.
10. Califano J., Van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W., Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Research. 56:1996;2488-2492.
11. Uzawa N., Yoshida M.A., Oshimura M., Ikeuchi T. Suppression of tumorigenicity in three different cell lines of human oral squamous cell carcinoma by introduction of chromosome 3p via microcell-mediated chromosome transfer. Oncogene. 11:1995;1997-2004.
12. Van der Riet P., Nawroz H., Hruban R.H., Corio R., Tokino K., Koch W., Sidransky D. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Research. 54:1994;1156-1158.
13. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., Hittelman W., Hong W.K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Medicine. 2:1996;682-685.
14. Bockmühl U., Schwendel A., Dietel M., Peterson I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Research. 56:1996;5325-5329.
15. MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of larynx. Oncogene. 15:1997;1445-1453.
16. Zhang S.-Y., Klein-Szanto A.J.P., Sauter E.R., Shafarenko M., Mitsunaga S., Nobori T., Carson D.A., Ridge J.A., Goodrow T.L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Research. 54:1994;5050-5053.
17. Lydiatt W.M., Murty V.V.V.S., Davidson B.J., Xu L., Dyomina K., Sacks P.G., Schantz S.P., Chaganti R.S.K. Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes, Chromosomes and Cancer. 13:1995;94-98.
18. Uzawa K., Suzuki H., Yokoe H., Tanzawa H., Sato K. Mutational state of p16/CDKN2 and VHL genes in squamous-cell carcinoma of the oral cavity. International Journal of Oncology. 7:1995;895-899.
19. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W., Ahrendt S., Eby Y., Sewell D., Nawroz H., Bartek J., Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Research. 56:1996;3630-3633.
20. Stone S., Jiang P., Dayananth P., Tavtigian S.V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the p16 (MTS1) locus. Cancer Research. 55:1995;2988-2994.
21. INK4a transcript. Cancer Research. 55:1995;2995-2997.
22. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
23. Zhang Y., Xiong Y., Yabrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
24. Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K. Multiple type of aberrations in the p16 (INK4a) and the p15 (INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. International Journal of Cancer. 70:1997;437-442.
25. Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Research. 57:1997;4868-4875.
26. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.-P.J., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Research. 55:1995;4525-4530.
27. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., Jones P.A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research. 55:1995;4531-4535.
28. Spruck III C.H., Gonzalez-Zulueta M., Shibata A., Simoneau A.R., Lin M.-F., Gonzales F., Tsai Y.C., Jones P.A. p16 gene in uncultured tumors. Nature. 370:1994;183-184.
29. INK4a in oral premalignant lesions. Oncogene. 14:1997;1799-1803.